Marker Therapeutics, Inc.: Business Overview, Financials & Competitive Analysis
Marker Therapeutics, Inc. scores 4/10 on the AskCyborg Cyborg Score (Mixed). Early-stage cell therapy company with differentiated MAR-T platform showing clinical promise but facing significant commercial and capital risk. The company demonstrates strong clinical validation with promising efficacy data in pancreatic cancer and analyst support (Strong Buy rating with 500%+ upside potential). However, pre-commercial stage, losses continuing through 2026-2027, extremely.
What is Marker Therapeutics, Inc.'s industry? Marker Therapeutics, Inc. (markerimmuno.com) operates in Oncology Drugs. AskCyborg classifies Marker Therapeutics, Inc. under Oncology Drugs in its company registry.
Marker Therapeutics is a clinical-stage immuno-oncology company developing novel cell-based immunotherapies and peptide-based vaccines for hematological malignancies and solid tumors. The company's lead program focuse...
Cyborg Score thesis
Early-stage cell therapy company with differentiated MAR-T platform showing clinical promise but facing significant commercial...
Read the full analyst-debate transcript →Get the Latest Marker Therapeutics, Inc. Report
Up-to-date AI-powered research, analyst debate audio & saved-company playlists
Get Current Report FreeMarker Therapeutics, Inc. Overview
Pro stress-test →Marker Therapeutics is a clinical-stage immuno-oncology company developing novel cell-based immunotherapies and peptide-based vaccines for hematological malignancies and solid tumors. The company's lead program focuses on Multi-Antigen Recognizing (MAR) T cell technology with promising early clinical data demonstrating both safety and efficacy.
Strategic Profile
Pro stress-test →The company's MAR-T cell technology achieved an 84.6% disease control rate in pancreatic cancer when combined with frontline chemotherapy. Marker plans a company-sponsored trial with expanded antigen targets, higher cell doses and lymphodepletion, with anticipated clinical initiation in H1 2026, supported by non-dilutive government funding.
Competitive Landscape
Pro stress-test →Marker competes in the CAR-T and multi-antigen T cell therapy space against established players including Juno Therapeutics (Celgene/Bristol Myers Squibb), Kite Pharma (Gilead), and emerging competitors. The MAR-T platform differentiates through multi-antigen targeting and apparent tolerability, though the company lacks commercial-stage competitors directly.
Industry Context
Marker Therapeutics, Inc. operates in Oncology Drugs.
Key facts
Founded: 1991 · Headquarters: Houston, TX · Employees: Unknown · Revenue: Minimal/Pre-commercial · Market cap: $~300M (micro-cap)